{"id":"NCT01425632","sponsor":"Mitsubishi Tanabe Pharma Corporation","briefTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis","officialTitle":"A Confirmatory Study of TAU-284 in Pediatric Patients With Perennial Allergic Rhinitis (A Randomized, Double-blind, Placebo-controlled Study)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2011-08","primaryCompletion":"2011-12","completion":"2011-12","firstPosted":"2011-08-30","resultsPosted":"2015-12-14","lastUpdate":"2015-12-14"},"enrollment":490,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["Perennial Allergic Rhinitis"],"interventions":[{"type":"DRUG","name":"TAU-284","otherNames":[]},{"type":"DRUG","name":"TAU-284","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"TAU-284 Low","type":"EXPERIMENTAL"},{"label":"TAU-284 High","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The objectives of this study are: to confirm the superiority of TAU-284 over placebo after two weeks of administration to pediatric patients with perennial allergic rhinitis, and to investigate the dose response, safety, and plasma concentrations of TAU-284.","primaryOutcome":{"measure":"Change From Baseline in Total Score for the Three Major Nasal Symptoms [Sneezing, Rhinorrhea, and Nasal Congestion] (at Final Evaluation)","timeFrame":"Baseline and Week 2","effectByArm":[{"arm":"TAU-284 Low","deltaMin":-0.84,"sd":0.12},{"arm":"TAU-284 High","deltaMin":-0.92,"sd":0.12},{"arm":"Placebo","deltaMin":-0.7,"sd":0.12}],"pValues":[]},"eligibility":{"minAge":"7 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":7},"locations":{"siteCount":5,"countries":["Japan"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":161},"commonTop":["Nasopharyngitis","Pharyngitis","Epistaxis"]}}